8月12日,恒瑞医药宣布其自主研发的1类新药海曲泊帕乙醇胺片的药品上市许可申请获中国国家药监局(NMPA)受理,适应症为:适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的原发免疫性血小板减少症(ITP)成人及≥6岁的儿童患者。原发免疫性血小板减少症(ITP)是一种获得性自身免疫性出血性疾病,临床表现以皮肤黏膜出血为主,严重者有内脏出血,甚至颅内出血而导致死亡,是儿童和青少年常见的出血性疾病。儿童...
Source Link8月12日,恒瑞医药宣布其自主研发的1类新药海曲泊帕乙醇胺片的药品上市许可申请获中国国家药监局(NMPA)受理,适应症为:适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的原发免疫性血小板减少症(ITP)成人及≥6岁的儿童患者。原发免疫性血小板减少症(ITP)是一种获得性自身免疫性出血性疾病,临床表现以皮肤黏膜出血为主,严重者有内脏出血,甚至颅内出血而导致死亡,是儿童和青少年常见的出血性疾病。儿童...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.